{"id":"pembrolizumab-vibostolimab-co-formulation","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This co-formulation combines pembrolizumab, a PD-1 inhibitor, with vibostolimab, a PD-L1 inhibitor. By blocking the PD-1/PD-L1 interaction, the immune system is able to recognize and attack cancer cells more effectively. This combination has shown promise in treating various types of cancer.","oneSentence":"Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:31.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05226598","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":739},{"nctId":"NCT04303169","phase":"PHASE1, PHASE2","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":146},{"nctId":"NCT05665595","phase":"PHASE3","title":"A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-19","conditions":"Melanoma","enrollment":1594},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-7684A"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab/Vibostolimab Co-Formulation","genericName":"Pembrolizumab/Vibostolimab Co-Formulation","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}